VISION
We strive to make drug discovery faster and smarter
for all researcher,
powered by AI agents
CULTURE
At the heart of our culture is a belief in the uniqueness of every team member. We create an environment that values individual strengths and skills, helping each person unlock their potential and make a meaningful impact.
Open feedback, support, and celebrating achievements together foster an atmosphere where personal and team growth go hand in hand.
We inspire one another with fresh ideas, learn together, mark important milestones, and move forward every day—toward innovation, excellence, and shared success
Introducing our team
QINGWEN CHEN
QINGWEN CHEN
Founder & CEO
During my AI X chemistry doctorate at Osaka University, a collaboration in information science sparked a vision: to transform drug discovery through AI. I founded DLeader to realize that vision by building a Closed-Loop Automatic AI Drug Discovery Platform.
Our mission is to create generative tools that support and accelerate AI-driven drug discovery (AIDD), empowering researchers with smarter, faster, and more collaborative innovation.
At DLeader, we strive to make advanced pharmaceutical research more efficient, accessible, and impactful for all.
TOM
TOM
Co-founder & CAIO
I believe AI4S (AI for Science) is the next major innovation that can push AI performance to new heights and revolutionize industries, particularly in drug discovery and cheminformatics.
I am passionate about this challenge because I’m convinced AI4S will spark the next wave of transformative progress in science and technology.
W. Y
W. Y
Co-founder & Interim CTO
Ph.D. in Engineering, University of Tokyo. Science is driven by passion and continuous innovation. I joined DLeader to pursue creativity and discovery in a collaborative environment.
Our shared goal is to develop practical and impactful research tools, and we're dedicated to making that a reality every day.
MIZUKI YASUDA
MIZUKI YASUDA
Co-founder & Interim COO
Graduate of Meiji University's School of Agriculture and a certified public accountant. Founded and successfully exited a plant factory startup. Currently in Friends Co., Ltd., engaged in product development support and investment ventures.
Joined DLeader upon resonating with the vision of founder Chen is a former intern at Friends, corp., and executed an investment to ensure the growth and success of DLeader.
I am dedicated to driving business growth in all aspects, including talent acquisition, funding, and product development.
ANN GRISHUNOVA
ANN GRISHUNOVA
Senior UI/UX designer
Graduated with honors from a Master’s program in Software Engineering. This foundation allows me to work at the intersection of technology and design: understanding how a product works “under the hood” and turning complex processes into a simple and intuitive user experience.
My portfolio includes product solutions for corporations, startups, and landing pages for various client niches.
STEVE
STEVE
Senior Frontend developer
Graduated with honors from a Master’s program in Software Engineering and later completed my postgraduate studies.
For over 10 years, I have been working in IT, combining the role of Senior frontend developer with teaching advanced programming at a university.
My experience includes building scalable, high-load web applications, working deeply with architecture, algorithms, and design patterns. I enjoy turning complex technical challenges into elegant and efficient solutions, as well as sharing my knowledge to help teams adopt best engineering practices.
Scientific advisers
D
Dr. Mizuguchi Kenji
prof. at Osaka University
Prof. Mizuguchi leads research that integrates informatics and computational chemistry to uncover the mechanisms of diseases and apply findings to drug discovery. His lab focuses on integrating diverse biological data—from genes and proteins to diseases and compounds—to power AI-driven analysis.
He also develops predictive models for protein structure, function, and interactions, with applications in fields like immunology and developmental biology, as well as early-stage drug profiling.
Link to Mizuguchi Lab
D
Dr. Nakatani Kazuhiko
prof. at Osaka University
Prof. Kazuhiko Nakatani is a leading expert in developing small molecules that target nucleic acids, focusing on those that recognize mismatched base pairs in triplet repeat sequences implicated in neurodegenerative diseases.
Recently, Nakatani group explore AI and computer-aided approaches in drug discovery research, advancing the design of novel therapeutic candidates.
Link to Nakatani Lab
D
Dr. Yamada Takeshi
Junior Associate Prof., Institute of Science Tokyo
Dr. Yamada Takeshi is a specialist in synthetic organic chemistry, chemical biology, and nucleic-acid drug development, serving as a lecturer at the Nucleotide and Peptide Drug Discovery Center (TIDE), Tokyo University of Science. His research focuses on designing antisense oligonucleotides (ASOs) and heteroduplex oligonucleotides (HDOs), particularly improving drug-delivery systems and pharmacokinetics to advance nucleic-acid therapeutics. He aims to contribute to next-generation treatments for challenging diseases through innovative oligonucleotide-based drugs.
Recently, Nakatani group explore AI and computer-aided approaches in drug discovery research, advancing the design of novel therapeutic candidates.
Link to Yamada Takeshi

Be the first to know about the app release!
Join to the waiting list

Person icon
Person icon
Company icon
Position icon
Email icon
Comment icon
Mobile version is in production